Plain-English translation of NCT06859775 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is a clinical trial testing a new immunotherapy drug called in combination with other standard treatments for people with cervical cancer that has come back or spread to other parts of the body. Researchers want to find the right dose of this medication and understand how well it works, along with what side effects patients may experience. About 100 women will participate across multiple hospitals.
Cervical cancer that returns or spreads is very difficult to treat, and current options have limited success. This trial explores whether adding this new immunotherapy medication to standard treatments might help more patients, by boosting the body's own immune system to fight the cancer.
You likely qualify if…
You likely don't qualify if…
You would receive injections of the new medication combined with standard chemotherapy treatments at regular clinic visits. The study has different treatment groups to determine the safest and most effective dose. You'll have blood tests, imaging scans, and checkups to monitor how you're responding and watch for side effects. The trial involves close follow-up for several months during treatment and beyond.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China